2026-04-14T00:42:23Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/134672025-10-24T10:58:12Zcom_2072_378068com_2072_378040col_2072_378090

00925njm 22002777a 4500 dc Amigó, Núria author Julve, Josep author Hernández, Marta author Ribalta, Josep author Guardiola, Montse author López-Lifante, Víctor-Miguel author Herrero-Alonso, Cecilia author Arteaga Pillasagua, Ingrid author Ortega, Emilio author Martínez-Micaelo, Neus author Franch-Nadal, Josep author Mauricio, Didac author Castelblanco, Esmeralda author Alonso Pedrol, Nuria author Torán-Monserrat, Pere author 2025-08-04T07:07:27Z 2025-08-04T07:07:27Z 2025-02-21 Biomarker; Cardiovascular events; Diabetes mellitus; Glycoproteins; Lipoproteins; Nuclear magnetic resonance spectroscopy; Type 2 diabetes Biomarcador; Esdeveniments cardiovasculars; Diabetis mellitus; glicoproteïnes; Lipoproteïnes Biomarcador; Eventos cardiovasculares; Diabetes mellitus; Glicoproteínas; Lipoproteínas Traditional risk factors cannot accurately predict cardiovascular events (CVE) in type 2 diabetes (T2D). The LIPOCAT study aimed to prospectively evaluate the clinical utility of advanced lipoprotein characteristics and glycoproteins to predict future cardiovascular events (CVE) in a large cohort of subjects with type 2 diabetes mellitus (T2D). From four different Spanish prospective cohorts, a total of 933 T2D subjects were selected to form the LIPOCAT study. Advanced 1H-Nuclear Magnetic Resonance (1H-NMR) analysis included lipoprotein (Liposcale®) and glycoprotein (Glycoscale) profiling. Random forest classification models and Area Under the Receiver Operating Characteristics (AUROC) analysis were used to assess the differential contribution of advanced variables in predicting CVE. Validation was performed using an external cohort. Out of 933 T2D subjects, 104 reported a CVE during follow-up. Analysis of Liposcale®/Glycoscale uncovered elevations in the circulating VLDL-cholesterol(C), remnant IDL-triglycerides (TG) and LDL-TG in subjects with CVE, along with glycoproteins (Glyc) A and B. Moreover, the incorporation of advanced Liposcale® variables to a base model constructed with traditional risk factors significantly improved the prediction of CVE, as evidenced by 1.5-fold increase in the C statistic (AUROC), reaching AUROC values of 0.756. In the independent validation cohort, similar improvements in AUROC values were observed by adding the advanced variables to the traditional models. Advanced 1H-NMR analysis revealed previously hidden lipoprotein and glycoprotein characteristics associated with CVE in T2D subjects. This work was supported by the Ministerio de Sanidad y Consumo and Instituto de Salud Carlos III through grant PI15/0625 (awarded to DM and EC), co-funded by the FEDER program “Una manera de hacer Europa.” Additional support was provided by Laboratorios Rubió S.A. through an unrestricted grant (LIPOCATV1FEB2018) for 1H-NMR characterization. http://hdl.handle.net/11351/13467 Diabetis no-insulinodependent Lipoproteïnes Glicoproteïnes DISEASES::Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Diabetes Mellitus::Diabetes Mellitus, Type 2 Other subheadings::Other subheadings::Other subheadings::/blood DISEASES::Cardiovascular Diseases Other subheadings::Other subheadings::/diagnosis CHEMICALS AND DRUGS::Lipids::Lipoproteins Other subheadings::Other subheadings::/analysis CHEMICALS AND DRUGS::Carbohydrates::Glycoconjugates::Glycoproteins ENFERMEDADES::enfermedades nutricionales y metabólicas::enfermedades metabólicas::trastornos del metabolismo de la glucosa::diabetes mellitus::diabetes mellitus tipo II Otros calificadores::Otros calificadores::Otros calificadores::/sangre ENFERMEDADES::enfermedades cardiovasculares Otros calificadores::Otros calificadores::/diagnóstico COMPUESTOS QUÍMICOS Y DROGAS::lípidos::lipoproteínas Otros calificadores::Otros calificadores::/análisis COMPUESTOS QUÍMICOS Y DROGAS::hidratos de carbono::glicoconjugados::glicoproteínas Advanced serum lipoprotein and glycoprotein profiling for cardiovascular event prediction in type 2 diabetes mellitus: the LIPOCAT study